Compare Bristol-Myers Squibb Co (BMY) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Invesco Solar ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.33 (market cap $116.30B), while Invesco Solar ETF trades at $56.4. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Invesco Solar ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| BMY | TAN | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $73.95 |
52-Week Low | $42.60 | $36.07 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Invesco Solar ETF (TAN) trades at $53.12, down 3.35% amid a bearish technical signal with 18 sell indicators. The fund focuses on utility-scale solar and grid technology, benefiting from AI-driven electricity demand but facing headwinds from policy uncertainty and supply chain costs. Recent news highlights both long-term growth potential and near-term volatility.
Outlook is mixed: strong structural demand for clean energy supports long-term growth, but regulatory risks and technical weakness pose challenges. Investors should weigh exposure to solar's AI-driven expansion against policy sensitivity and current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
